Covid-19 roundup: Mod­er­na notes high­er my­ocardi­tis risk for young males when com­pared to Pfiz­er's vac­cine; EMA signs off on Roche, Cell­tri­on mAb treat­ments

Mod­er­na’s new CMO Paul Bur­ton spoke to re­porters Thurs­day morn­ing, at­tempt­ing to de­fend his com­pa­ny’s vac­cine against ques­tions around heart-re­lat­ed risks that ap­pear to be …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER